PureIMS preparing for Series A financing round aiming to bring its two lead programs to marketing authorization
Roden — December 16, 2020 — PureIMS today announced that it is participating in Biotech Showcase™ Digital 2021, and providing an on-demand company presentation.
Bram van Dijck, CEO, will be presenting PureIMS at Biotech Showcase Digital.
PureIMS is a clinical stage pharmaceutical and medication systems company developing a portfolio of products addressing acute medical needs. These products are based on the company’s proprietary, preloaded and disposable dry powder inhaler (DPI) Cyclops™. Its design and functionality imply low COG and are patent protected until 2034. The company’s strategic focus is on products qualifying for accelerated marketing authorization, e.g. through the 505(b)(2) regulatory pathway. One Cyclops™ application is already on the market under a compassionate use regimen.
The company is aiming at a Series A financing round of around €20M-€25M to pursue its Cyclops™-based lead programs (currently in Phase 2 in neurology and allergy) to market authorization through accelerated regulatory routes.
Bram van Dijck, CEO at PureIMS, commented: “It is a particularly great opportunity to participate in this year’s Biotech Showcase Digital which coincides with PureIMS preparing for its Series A financing round. As our strategy focuses on bringing our lead products to the US and European market we look forward to meeting VCs during the Biotech Showcase Digital and welcome this opportunity to raise traction from their side to contribute to our imminent funding round.”
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.
“We are delighted that PureIMS will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
About Biotech Showcase
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
PureIMS is a clinical-stage pharmaceutical and medication systems company focused on developing and commercializing innovative inhaled therapies for the treatment of systemic and respiratory diseases with significant unmet medical needs. Cyclops™ is an easy-to-use, pre-filled, disposable dry powder inhaler (DPI) that is developed for inhalation powders and can be produced in a cost-effective way because of its simple yet sophisticated proprietary design. Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages compared to standard-of-care DPIs across key therapeutic areas. These attributes enable the hygienic and effective use on a worldwide scale.
PureIMS’ lead candidates, Levodopa Cyclops™ and Epinephrine Cyclops™, are in the final development stage as rescue therapies for OFF-episodes in Parkinson’s disease and allergy induced anaphylaxis, respectively. One product, Colistin Cyclops™, is already marketed and reimbursed under a compassionate use regimen for the treatment of cystic fibrosis patients. PureIMS recently conducted an open-label Phase I clinical trial with promising results for Hydroxychloroquine Cyclops™ for intervention in SARS-CoV-2 and possible future coronavirus outbreaks.
For more information, press and investors only:
Bram van Dijck
+31(0)50 205 3325